The letter referring to our article[1] on sticky platelet syndrome (SPS) by G. J. Ruiz-Arguelles[2] is both valuable and very interesting, as it refers to new prospective data[3] from a rather large patient cohort (n = 55) on this syndrome that were not available at the time of the preparation of our original review.[1] These data are in concordance with the published as well as our own experience and confirm that antiplatelet drugs such as acetylsalicylic acid (ASA) are efficient in both treatment of thrombosis and prevention of rethrombosis in this syndrome. In our cohort of 270 patients, we observed comparable (e.g., low ≤5%) rates of rethrombosis and normalization of aggregation pattern after the initiation of the antiplatelet therapy in the vast majority (> 90%) of patients. In most cases, these results were achieved solely by the treatment with ASA.[1]
However, it is important to mention that such treatment could be applied to the cases with an isolated defect. In combined defects (e.g., SPS with FV Leiden/PII20210/etc.), the situation may be more complex.
